AR007759A1 - Nuevos compuestos heterociclicos, el uso de los mismos para preparar composiciones farmaceuticas, un procedimiento para su preparacion ycomposiciones farmaceuticas que los comprenden. - Google Patents
Nuevos compuestos heterociclicos, el uso de los mismos para preparar composiciones farmaceuticas, un procedimiento para su preparacion ycomposiciones farmaceuticas que los comprenden.Info
- Publication number
- AR007759A1 AR007759A1 ARP960102088A AR10208896A AR007759A1 AR 007759 A1 AR007759 A1 AR 007759A1 AR P960102088 A ARP960102088 A AR P960102088A AR 10208896 A AR10208896 A AR 10208896A AR 007759 A1 AR007759 A1 AR 007759A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- pharmaceutical compositions
- alkoxy
- hydrogen
- trifluoromethyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000000917 hyperalgesic effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000001991 pathophysiological effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a un compuesto heterocíclico que tiene la fórmula (I), donde R1 y R2 independientemente son hidrógeno, halógeno, trifluormetilo,NR6R7, hidroxi, alquilo C1-6 o alcoxi C1-6; Y es >N-CH2, >CH-CH2- o >C=CH- donde únicamente el átomos ubrayado participa en el sistema de anillo;X es -O-, -S-, -C(R6R7)-, -CH2CH2-, -CH=CH-CH2, -CH2-CH=CH-, -CH2-(C=O)-, -(C=O)-CH2-; -CH2CH2CH2-; -CH=CH-, -N(R8)-(C=O)-, -(C=O)-N(R8)-, -O-CH2-,-CH2-O-, -S-CH2-,-CH2-S-, -(C=O)-, -N(R8)- o -(S=O)- d onde R6, R7, R8 y R9 son independientemente hidrógeno o alquilo C1-6; r es 1, 2 ó 3; Z estáseleccionado del Grupo (II), donde n es 1 ó 2; y R3 es -(CH2)m es -(CH2)mOH ó -(CH2)pCOR4 donde m es 0,1,2, 3, 4, 5 ó 6 y p es 0 ó 1 y donde R4 es -OH, -NH2,-NHOH o alcoxi C1-16; y R5 es hidrógeno, halógeno, trifluormetilo, hidroxi, alquilo C1-6 o alcoxi C1-6; y R10 es hidrógeno, alquilo C1-6, alcoxi C1-6 ofenilo opcionalmente substituido con halógeno, trifluormetilo, hidroxi, alquilo C1-6o alc oxi C1-6; y R11 es hidrógeno o alquilo C1-6; y :| es opcionalmenteun enlace simple o un doble enlace; o una sal del mismo farmacéuticamente aceptable; al procedimiento para su preparación, a las composiciones que loscontienen y a su usopara pr eparar composiciones farmacéuticas para el tratamiento clínico de condiciones dolorosas hiperalgésicas y/o inflamatoriasen las cuales las fibras c juegan un rol patofisiológico al producir dolor neurogénico e inflamación ytambién para el tratamiento de la resistencia a lainsulina en diabetes mellitus que no depende de insulina o del envejecimiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK40595 | 1995-04-07 | ||
| DK100595 | 1995-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007759A1 true AR007759A1 (es) | 1999-11-24 |
Family
ID=26063928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960102088A AR007759A1 (es) | 1995-04-07 | 1996-04-03 | Nuevos compuestos heterociclicos, el uso de los mismos para preparar composiciones farmaceuticas, un procedimiento para su preparacion ycomposiciones farmaceuticas que los comprenden. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5874428A (es) |
| EP (1) | EP0820451B1 (es) |
| JP (1) | JPH11503127A (es) |
| KR (1) | KR100466915B1 (es) |
| CN (1) | CN1152030C (es) |
| AR (1) | AR007759A1 (es) |
| AT (1) | ATE231144T1 (es) |
| AU (1) | AU708010B2 (es) |
| CA (1) | CA2217197A1 (es) |
| CZ (1) | CZ291294B6 (es) |
| DE (1) | DE69625806T2 (es) |
| DK (1) | DK0820451T3 (es) |
| ES (1) | ES2191090T3 (es) |
| HU (1) | HUP9800719A3 (es) |
| IL (1) | IL117810A (es) |
| MX (1) | MX9707531A (es) |
| NO (1) | NO974605L (es) |
| PL (1) | PL187171B1 (es) |
| RU (1) | RU2244713C2 (es) |
| TW (1) | TW419463B (es) |
| UA (1) | UA54385C2 (es) |
| WO (1) | WO1996031498A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6239148B1 (en) * | 1994-01-04 | 2001-05-29 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters thereof |
| AU729415B2 (en) | 1996-07-12 | 2001-02-01 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6323206B1 (en) | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| ZA978792B (en) * | 1996-10-04 | 1998-04-06 | Novo Nordisk As | N-substituted azaheterocyclic compounds. |
| EP0934312B1 (en) * | 1996-10-04 | 2003-03-19 | Novo Nordisk A/S | 1,4-disubstituted piperazines |
| JP2002508353A (ja) * | 1997-12-17 | 2002-03-19 | ノボ ノルディスク アクティーゼルスカブ | 新規ヘテロ環式化合物 |
| US6048856A (en) * | 1997-12-17 | 2000-04-11 | Novo Nordisk A/S | Heterocyclic compounds |
| US6613905B1 (en) * | 1998-01-21 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AU2331999A (en) * | 1998-01-21 | 1999-08-09 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
| US6509346B2 (en) * | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| JP2002501052A (ja) | 1998-01-21 | 2002-01-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | ケモカイン受容体アンタゴニストおよびその使用方法 |
| AU2825999A (en) * | 1998-03-17 | 1999-10-11 | Novo Nordisk A/S | Novel heterocyclic compounds |
| US6214816B1 (en) | 1998-03-17 | 2001-04-10 | Novo Nordisk A/S | Heterocyclic compounds |
| US6503926B2 (en) | 1998-09-04 | 2003-01-07 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US7271176B2 (en) * | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US7355042B2 (en) * | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
| US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| TWI291467B (en) * | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
| HUE026904T2 (en) | 2003-04-24 | 2016-08-29 | Incyte Holdings Corp | Aza-spiroalkane derivatives as inhibitors of metalloproteases |
| US20070066570A1 (en) * | 2003-06-16 | 2007-03-22 | Michael Solomon | Methods for treating sleep disorders |
| SI2041088T1 (sl) | 2006-06-28 | 2014-05-30 | Amgen Inc. | Inhibitorji transporter-1 glicina |
| AU2017311691B2 (en) * | 2016-08-18 | 2021-12-02 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE562299A (es) * | 1956-11-15 | |||
| FR1296519A (fr) * | 1959-05-05 | 1962-06-22 | Abbott Lab | Procédé pour la préparation de phénothiazines substituées sur l'azote, de préférence par un groupe pyrrolidinoalkyle substitué |
| DE1159954B (de) * | 1961-11-25 | 1963-12-27 | Boehringer & Soehne Gmbh | Verfahren zur Herstellung neuer 10-(Alkoxypiperidinopropyl)-phenthiazine und ihrer Salze |
| CH454871A (de) * | 1964-01-24 | 1968-04-30 | Geigy Ag J R | Verfahren zur Herstellung von neuen Salzen der Embonsäure |
| GB1517385A (en) * | 1975-08-29 | 1978-07-12 | Eisai Co Ltd | Phenothiazine derivatives |
| MY113463A (en) * | 1994-01-04 | 2002-03-30 | Novo Nordisk As | Novel heterocyclic compounds |
-
1996
- 1996-01-04 UA UA97104938A patent/UA54385C2/uk unknown
- 1996-03-28 US US08/623,289 patent/US5874428A/en not_active Expired - Fee Related
- 1996-04-01 DK DK96907327T patent/DK0820451T3/da active
- 1996-04-01 DE DE69625806T patent/DE69625806T2/de not_active Expired - Fee Related
- 1996-04-01 ES ES96907327T patent/ES2191090T3/es not_active Expired - Lifetime
- 1996-04-01 RU RU97118474/04A patent/RU2244713C2/ru not_active IP Right Cessation
- 1996-04-01 CZ CZ19973164A patent/CZ291294B6/cs not_active IP Right Cessation
- 1996-04-01 HU HU9800719A patent/HUP9800719A3/hu unknown
- 1996-04-01 AU AU51003/96A patent/AU708010B2/en not_active Ceased
- 1996-04-01 JP JP8529868A patent/JPH11503127A/ja not_active Ceased
- 1996-04-01 CN CNB961937793A patent/CN1152030C/zh not_active Expired - Fee Related
- 1996-04-01 KR KR1019970707083A patent/KR100466915B1/ko not_active Expired - Fee Related
- 1996-04-01 PL PL96322722A patent/PL187171B1/pl not_active IP Right Cessation
- 1996-04-01 WO PCT/DK1996/000139 patent/WO1996031498A1/en not_active Ceased
- 1996-04-01 EP EP96907327A patent/EP0820451B1/en not_active Expired - Lifetime
- 1996-04-01 AT AT96907327T patent/ATE231144T1/de not_active IP Right Cessation
- 1996-04-01 CA CA002217197A patent/CA2217197A1/en not_active Abandoned
- 1996-04-01 MX MX9707531A patent/MX9707531A/es unknown
- 1996-04-03 IL IL11781096A patent/IL117810A/en not_active IP Right Cessation
- 1996-04-03 AR ARP960102088A patent/AR007759A1/es unknown
- 1996-05-14 TW TW085104810A patent/TW419463B/zh not_active IP Right Cessation
-
1997
- 1997-10-06 NO NO974605A patent/NO974605L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL187171B1 (pl) | 2004-05-31 |
| AU708010B2 (en) | 1999-07-29 |
| HUP9800719A3 (en) | 1999-09-28 |
| NO974605L (no) | 1997-12-04 |
| CZ291294B6 (cs) | 2003-01-15 |
| ES2191090T3 (es) | 2003-09-01 |
| MX9707531A (es) | 1997-11-29 |
| CA2217197A1 (en) | 1996-10-10 |
| ATE231144T1 (de) | 2003-02-15 |
| US5874428A (en) | 1999-02-23 |
| CN1152030C (zh) | 2004-06-02 |
| DE69625806T2 (de) | 2004-01-22 |
| HUP9800719A2 (hu) | 1999-06-28 |
| DK0820451T3 (da) | 2003-05-12 |
| EP0820451A1 (en) | 1998-01-28 |
| IL117810A0 (en) | 1996-08-04 |
| RU2244713C2 (ru) | 2005-01-20 |
| AU5100396A (en) | 1996-10-23 |
| PL322722A1 (en) | 1998-02-16 |
| JPH11503127A (ja) | 1999-03-23 |
| WO1996031498A1 (en) | 1996-10-10 |
| TW419463B (en) | 2001-01-21 |
| DE69625806D1 (de) | 2003-02-20 |
| EP0820451B1 (en) | 2003-01-15 |
| CN1183781A (zh) | 1998-06-03 |
| CZ316497A3 (cs) | 1998-03-18 |
| UA54385C2 (uk) | 2003-03-17 |
| NO974605D0 (no) | 1997-10-06 |
| KR100466915B1 (ko) | 2005-04-14 |
| KR19980703684A (ko) | 1998-12-05 |
| IL117810A (en) | 2001-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR007759A1 (es) | Nuevos compuestos heterociclicos, el uso de los mismos para preparar composiciones farmaceuticas, un procedimiento para su preparacion ycomposiciones farmaceuticas que los comprenden. | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| DE122009000040I2 (de) | Naphthalin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen. | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| ATE7689T1 (de) | 1-(dihydroxyphenyl)-2-amino-aethanol-derivate, verfahren und mittel zu ihrer herstellung sowie diese derivate enthaltende mittel. | |
| ES2160640T3 (es) | Nuevos (r)-5-carbamoil-8-fluoro-3-amino disustituido en n,n-3,4-dihidro-2h-1-benzopiranos. | |
| PA8432901A1 (es) | Compuestos de piridilpirrol | |
| ATE38834T1 (de) | 5-substituierte 1,2,4-oxadiazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| MX9302957A (es) | Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| FR2645537B1 (fr) | Nouveaux sulfonamides derives d'acides benzocycliques ou benzoheterocycliques, leur preparation et leur application en therapeutique | |
| HUP0001396A2 (hu) | 3-Amino-3 aril-propán-1-ol-származékok, előállításuk és felhasználásuk | |
| IT1317048B1 (it) | Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie | |
| UY28688A1 (es) | Derivados de amida | |
| AR046874A1 (es) | Nuevos metodos | |
| BG51155A3 (bg) | Метод за получаване на производни на нафталина | |
| PE20020426A1 (es) | ß-TIO-a-AMINOACIDOS, PROCEDIMIENTOS PARA SU PREPARACION Y MEDICAMENTOS QUE LOS CONTIENEN | |
| ES2183492T3 (es) | Nuevos derivados de nitrono,su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion | |
| ES2135695T3 (es) | Derivados de aminoacidos y su uso como inhibidores de la fosfolipasa a2. | |
| CO4960654A1 (es) | Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la cocaina u otros estimulantes psicomotores | |
| AR036131A1 (es) | Derivados de benzo (g) quinolina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la fabricacion de un medicamento | |
| FR2617476B1 (fr) | Nouveaux derives polycycliques aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique | |
| ES2086528T3 (es) | Nuevos compuestos biciclicos sustituidos con amino. | |
| ES2093246T3 (es) | Compuestos de benzazepina terapeuticos. | |
| AR041954A1 (es) | Un proceso para preparar acetato de risperidona y compuestos intermediarios para dicho proceso |